VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the expansion of two research collaborations to align with its recently announced collaboration with the Deep Docking AI Drug Discovery Platform..

不列颠哥伦比亚省温哥华，2024年5月8日（环球通讯社）--Rakovina Therapeutics Inc.（TSX-V:RKV，“公司”或“Rakovina Therapeutics”）是一家致力于推进基于新型DNA损伤反应技术的新型癌症治疗的生物制药公司，很高兴宣布扩大两项研究合作，以配合其最近宣布的与深度对接AI药物发现平台的合作。。

On March 27, 2024, the Company announced an agreement granting Rakovina Therapeutics exclusive access to the proprietary Deep Docking AI platform for DNA-damage response targets. Using the Deep Docking AI platform, the Company is analyzing billions of molecular structures to evaluate their potential as targeted cancer drugs..

2024年3月27日，该公司宣布了一项协议，允许Rakovina Therapeutics独家访问专有的深度对接AI平台，用于DNA损伤反应目标。利用深度对接AI平台，该公司正在分析数十亿个分子结构，以评估其作为靶向癌症药物的潜力。。

“These partnerships allow us to capitalize on the Deep Docking AI platform while maintaining high standards of research,” said Rakovina Therapeutics Executive Chairman, Jeffrey Bacha. “The most promising lead candidates will be validated using the Company’s established R&D infrastructure and advanced to human clinical trials and pharmaceutical partnerships.”.

Rakovina Therapeutics执行主席Jeffrey Bacha说：“这些合作关系使我们能够利用深度对接AI平台，同时保持高标准的研究。”。“最有希望的潜在客户将通过公司建立的研发基础设施进行验证，并推进人体临床试验和药物合作。”。

To support these drug development efforts, the Company has expanded a collaboration with Pharma Inventor Inc., a British Columbia-based chemistry R&D and analytical services company serving pharmaceutical and biotech industries, as well as research institutes and academic research groups across North America.

为了支持这些药物开发工作，该公司扩大了与Pharma Inventor Inc.的合作，Pharma Inventor Inc.是一家总部位于不列颠哥伦比亚省的化学研发和分析服务公司，服务于制药和生物技术行业，以及北美各地的研究机构和学术研究团体。

Pharma Inventor has agreed to provide medicinal chemistry support to rapidly synthesize novel lead drug candidates identified by the Deep Docking AI platform for further validation by the Company. Rakovina Therapeutics will own all rights to novel molecules developed through the collaboration.  .

Pharma Inventor已同意提供药物化学支持，以快速合成由深度对接AI平台确定的新型先导候选药物，以供公司进一步验证。Rakovina Therapeutics将拥有通过合作开发的新型分子的所有权利。。

The Company has also extended and expanded its collaborative research agreement with the University of British Columbia (UBC). Rakovina Therapeutics’ established lead optimization research infrastructure at the University’s Vancouver Prostate Center will provide rapid validation of novel drug candidates identified through the Deep Docking AI platform..

该公司还扩展了与不列颠哥伦比亚大学（UBC）的合作研究协议。Rakovina Therapeutics在该大学温哥华前列腺中心建立的铅优化研究基础设施将为通过深度对接AI平台确定的新型候选药物提供快速验证。。

According to Rakovina Therapeutics President and Chief Scientific Officer, Dr. Mads Daugaard, “We are expanding these important research collaborations to support the company's recently announced collaboration with the Deep Docking AI platform. This ramp-up will position us to capitalize on the opportunity of this collaboration.”.

据Rakovina Therapeutics总裁兼首席科学官Mads Daugaard博士表示，“我们正在扩大这些重要的研究合作，以支持该公司最近宣布的与深度对接AI平台的合作。这次合作将使我们能够利用这次合作的机会。”。

“Over the next 12 to 16 weeks, we intend to screen six to eight billion compounds against our initial DDR target and anticipate synthesizing a short-list of the most promising novel drug candidates for in vitro and in vivo validation through our in-house laboratory infrastructure,” he added. Dr. Daugaard is also a professor at UBC..

“在接下来的12至16周内，我们打算针对我们最初的DDR目标筛选60至80亿种化合物，并预计通过我们的内部实验室基础设施合成一份最有希望的候选新药短名单，用于体外和体内验证，”他补充道。Daugaard博士也是UBC的教授。。

“Our goal is to advance promising lead candidates toward clinical trials through collaboration with pharmaceutical development partners. With recent announcements of pre-clinical licensing deals in the DNA-damage response arena, we're confident in our ability to generate shareholder value in the near term,” said Bacha..

Bacha说：“我们的目标是通过与药物开发合作伙伴的合作，推动有希望的主要候选人进入临床试验。随着最近在DNA损伤反应领域宣布的临床前许可协议，我们有信心在短期内创造股东价值。”。。

About Rakovina Therapeutics Inc.

关于Rakovina Therapeutics Inc。

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies.  The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies.

Rakovina Therapeutics Inc.专注于基于新型DNA损伤反应技术开发新的癌症治疗方法。该公司已经建立了一系列新型DNA损伤反应抑制剂，旨在将一种或多种候选药物推进人体临床试验，并获得加拿大卫生部、美国食品和药物管理局以及类似国际监管机构对新型癌症治疗剂的上市批准。

Further information may be found at www.rakovinatherapeutics.com..

更多信息请访问www.rakovinatherapeutics.com。。

About Pharma Inventor Inc.

关于Pharma Inventor Inc。

Pharma Inventor Inc. is a Canadian chemistry research and development and analytical services company located in Vancouver, British Colombia. Pharma Inventor was established in 2013 to provide inventive and high-quality medicinal chemistry solutions in drug discovery research. Pharma Inventor has established a state-of-the-art medicinal chemistry facility relevant to AI-based drug discovery.

Pharma Inventor Inc.是一家加拿大化学研发和分析服务公司，位于不列颠哥伦比亚省温哥华。Pharma Inventor成立于2013年，旨在为药物发现研究提供创造性和高质量的药物化学解决方案。Pharma Inventor建立了与基于AI的药物发现相关的最先进的药物化学设施。

Its skilled team of international scientists serve the needs of pharmaceutical, biotech, research institutes and academic research groups to expedite their discovery R&D projects with innovative chemistry solutions. Further information may be found at www.pharmainventor.com..

其技术娴熟的国际科学家团队服务于制药、生物技术、研究机构和学术研究团体的需求，以创新的化学解决方案加速其发现研发项目。有关更多信息，请访问www.pharmainventor.com。。

About the Vancouver Prostate Center at the University of British Columbia

关于不列颠哥伦比亚大学温哥华前列腺中心

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities.  It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research. The VPC hosted by the Vancouver Coastal Health Research Institute and the University of British Columbia.

温哥华前列腺中心（VPC）取得了成功，因此它被誉为世界上最受尊重的癌症设施之一。它是一个国家卓越中心，也是商业化和研究的指定卓越中心。VPC由温哥华海岸健康研究所和不列颠哥伦比亚大学主办。

Its research capabilities range from molecular biology to functional genomics and human clinical trials..

其研究能力从分子生物学到功能基因组学和人类临床试验。。

The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

TSXV既不批准也不反对本新闻稿的内容。TSXV及其监管服务提供商（定义见TSXV政策）均不对本版本的充分性或准确性负责。

Notice Regarding Forward-Looking Statements:

关于前瞻性声明的通知：

This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company; the Company’s commitment to advancing new cancer therapies; the ability of the Company to extract value from the Deep Docking AI platform; the Company’s ability to execute on its business plans while maintaining high standards of research; the ability of Pharma Inventor Inc.

本版本包括有关公司及其各自业务的前瞻性声明，其中可能包括但不限于有关公司拟议业务计划的声明；该公司致力于推进新的癌症疗法；公司从深度对接AI平台中提取价值的能力；公司在保持高标准研究的同时执行其商业计划的能力；Pharma Inventor Inc.的能力。

to accurately provide medicinal chemistry support; the projected timeline and effectiveness of the Company’s strategy to utilize the Deep Docking AI platform; and the Company’s ability to generate shareholder value.. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved.

准确提供药物化学支持；公司利用深度对接AI平台的战略的预计时间表和有效性；以及公司创造股东价值的能力。。通常（但并非总是如此）前瞻性陈述可以通过使用诸如“计划”、“预期”、“预期”、“预定”、“打算”、“设想”、“预期”、“相信”、“提议”或此类词语和短语的变体（包括负面变体）来识别，或者声明某些行动、事件或结果“可能”、“可能”、“会”、“可能”或“将”被采取、发生或实现。

Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition..

此类声明基于公司管理层当前的期望。本新闻稿中讨论的前瞻性事件和情况可能不会在特定日期发生，也可能根本不会发生，并且可能由于影响公司的已知和未知风险因素和不确定性而产生重大差异，包括医疗器械行业风险、经济因素、监管因素、股票市场以及与增长和竞争相关的风险。。

Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended.

虽然本公司试图确定可能导致实际行动、事件或结果与前瞻性声明中描述的有重大差异的重要因素，但可能还有其他因素导致行动、事件或结果与预期、估计或预期的不同。

No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.   The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedar.com..

不能保证前瞻性声明。除适用证券法要求外，前瞻性声明仅在其作出之日起生效，公司没有义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件或其他原因。读者可以参考该公司最新的SEDAR文件，以更完整地讨论所有适用的风险因素及其潜在影响，其副本可通过该公司的简介页面访问，网址为www.SEDAR.com。。

For Further Information Contact:

欲了解更多信息，请联系：

David Hyman, Chief Financial Officer

首席财务官David Hyman

info@rakovinatehrapeutics.com

info@rakovinatehrapeutics.com

Invest Relations & Media

投资关系与媒体

Ira M. Gostin

Ira M.Gostin

ir@rakovinatherapeutics.com

ir@rakovinatherapeutics.com

775-391-0213

775-391-0213